Home > Boards > US Listed > Biotechs >

Aurinia Pharmaceuticals Inc (AUPH)

Add AUPH Price Alert      Hide Sticky   Hide Intro
Moderator: Jesspro
Search This Board: 
Last Post: 9/24/2020 4:52:38 PM - Followers: 187 - Board type: Free - Posts Today: 0

Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need.

*Aurinia Pharmaceuticals Inc.





Candidate & Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Market
VOCLOSPORINLupus Nephritis (LN)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started

Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.

The Voclosporin Advantage

Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).

Voclosporin Could Transform the LN treatment Landscape

Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.

Advantages of Voclosporin Combined with Standard of Care (SoC)

Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.

Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:

  • Improved efficacy
    Increased safety
    Oral administration
    Improved average time to renal response or remission
    Improved duration of renal response
    Reduction in steroid burden
    Potential first line add-on to MMF
    Fewer toxic immunosuppressants required
Benefits of Voclosporin

Potential Benefits of Voclosporin

In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.

The list of potential product benefits includes:

LN Critical Need Voclosporin (based on AURA Results)
Control of Active Disease
Rapid Disease Control
Lower Steroid Burden
Impact on Extra-renal disease
Convenient Treatment Regimen

In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s

Well Characterized Safety Profile

Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.

No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#11105   Maybe 40....DES and LN greggors 09/24/20 04:52:38 PM
#11104   Yo u mean 30, Cervelo? Ganz 09/24/20 10:20:42 AM
#11103   let us hope this gets fda approval we cervelo 09/24/20 09:48:26 AM
#11102   Ha, I’m with ya Slim, but to me Ganz 09/23/20 05:10:42 PM
#11101   $2, then bankruptcy? Jesspro 09/23/20 04:21:31 PM
#11100   hey we are only down 10% and it cervelo 09/23/20 04:12:06 PM
#11099   Market is looking like 1999 again. It will biotech_researcher 09/23/20 12:27:42 PM
#11098   Thank you, that is a very helpful article nferna 09/23/20 11:28:22 AM
#11097   Everyone has an opinion on options, I personally slimhere 09/23/20 10:53:05 AM
#11096   Nice! I'm very much an amateur when nferna 09/23/20 09:53:25 AM
#11095   I sold 10 contracts of AUPH Oct 16 slimhere 09/23/20 08:34:35 AM
#11094   Sky is falling. Watch out for $2 pps. Jesspro 09/23/20 08:05:53 AM
#11093   why not? seems when we get a good cervelo 09/22/20 02:30:04 PM
#11092   Why so weak? biotech_researcher 09/22/20 10:30:59 AM
#11091   Wish I bought PUTS. Crappy action. I was biotech_researcher 09/22/20 10:30:27 AM
#11090   Sold Oct $15 puts for 1.50 nferna 09/22/20 10:22:32 AM
#11089   Ganz, IMO, the Market Makers move this stock slimhere 09/21/20 03:19:50 PM
#11088   For a laugh, read this phony BS story moosedogger 09/18/20 03:11:03 PM
#11087   Nice Jesspro, and we’re moving today! Ganz 09/18/20 03:01:21 PM
#11086   KZR still at it, LE & LN lidopete 09/17/20 05:47:23 PM
#11085   https://finance.yahoo.com/news/hedge-funds-t-stop-buying-192604381.html Jesspro 09/16/20 04:17:12 PM
#11084   AMRN reportedly looking at an “authorized generic” version north40000 09/15/20 05:25:35 PM
#11083   Nice Bio! Ganz 09/15/20 11:08:10 AM
#11082   Wow, you called him everything in the book biotech_researcher 09/15/20 06:51:37 AM
#11081   True on all points Merc. Anyone listening to Ganz 09/14/20 03:01:53 PM
#11080   Technically, IMMU ytd, was at low of Merc1 09/14/20 02:31:21 PM
#11079   John Thero over at Amarin is a CPA slimhere 09/14/20 02:05:16 PM
#11077   Awesome! Could you please follow up with nferna 09/14/20 10:02:33 AM
#11076   I believe most are overpaid; however, I'll pick zzaatt 09/14/20 09:56:28 AM
#11075   I have a new friend, our company is slimhere 09/14/20 08:34:20 AM
#11074   It is your money, but I had AMRN slimhere 09/14/20 08:21:54 AM
#11073   Slim, your chance of a reply are pretty biotech_researcher 09/13/20 05:17:10 PM
#11072   a shareholder that bought at 18.0 deserves an cervelo 09/13/20 02:25:06 PM
#11071   That’s not music to the GF’s ears. Jesspro 09/13/20 10:48:18 AM
#11070   Just for the record, one year ago we nferna 09/13/20 08:20:18 AM
#11069   I believe most are overpaid; however, I'll pick slimhere 09/12/20 09:55:10 PM
#11068   well slim I would not count on that cervelo 09/10/20 05:19:37 PM
#11067   Slim, I hope he answers your letter. AMRN Jesspro 09/10/20 03:59:36 PM
#11066   Slim, that is hilarious! Ganz 09/10/20 11:43:30 AM
#11065   Jess, take a look at AMRN's stock price, slimhere 09/10/20 11:17:38 AM
#11064   Slim, that is the right question, even though Jesspro 09/10/20 09:58:23 AM
#11063   https://finance.yahoo.com/news/aurinia-pharmaceuticals-present-three-upcoming-10 thesaud 09/10/20 09:07:00 AM
#11062   Maybe I'll call in with my question: slimhere 09/10/20 06:48:02 AM
#11061   September 10, 2020 slimhere 09/10/20 06:32:18 AM
#11060   no it is not covid or cancer related cervelo 09/09/20 05:11:50 PM
#11059   Aurina stock performance has been lack luster since biotech_researcher 09/09/20 11:17:37 AM
#11058   I tend to agree with this author on biotech_researcher 09/09/20 11:12:11 AM
#11057   https://seekingalpha.com/article/4373010-potential-positive-readout-of-aurinia-p thesaud 09/09/20 06:43:34 AM
#11056   https://seekingalpha.com/article/4373010-potential-positive-readout-of-aurinia-p thesaud 09/09/20 06:43:26 AM
#11055   do not hold your breath, unlike other stocks cervelo 09/08/20 05:58:20 PM
Consent Preferences